Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biofrontera Inc. (NASDAQ: BFRI) SEC filings page provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Biofrontera is a U.S.-based biopharmaceutical company focused on dermatology and photodynamic therapy (PDT), commercializing Ameluz® and the RhodoLED® lamp series for actinic keratoses and developing additional indications such as superficial basal cell carcinoma and acne vulgaris.
Through its current and periodic reports, investors can review how Biofrontera describes its business, risk factors and financial condition. Form 8-K filings document material events, including quarterly financial results, strategic transactions with Biofrontera AG to acquire all U.S. rights to Ameluz® and RhodoLED®, private placements of Series C and Series D convertible preferred stock, and the divestiture of the Xepi® antibiotic cream license. Other 8-Ks detail Nasdaq listing compliance notices and stockholder meeting outcomes.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically include information on revenues from dermatology products, operating expenses, liquidity, and discussions of clinical and regulatory progress for Ameluz®-PDT. These filings also outline the company’s reliance on product sales, competition in dermatology, intellectual property matters, and other risks relevant to its PDT-focused business model.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as revenue trends, changes in earnout structures, capital raises, and outcomes of clinical and regulatory milestones. Investors can also use this page to monitor Form 4 insider transaction reports, as well as proxy and registration statements that discuss governance, capital structure and preferred stock offerings.
By combining real-time EDGAR updates with AI-generated insights, this page offers a structured view of Biofrontera’s regulatory history, financial reporting, and material corporate events tied to its dermatology and photodynamic therapy strategy.
Biofrontera Inc. finalized agreements with Biofrontera AG to acquire all U.S. rights to Ameluz and RhodoLED. As part of the deal, the company will pay an earnout of 12% of U.S. Ameluz revenues in years when U.S. net sales are $65.0 million or less and 15% in years when they exceed $65.0 million. This replaces the prior transfer-pricing model under the now-terminated license and supply agreement.
The company also closed the second tranche of its private placement, issuing 2,500 Series C Convertible Preferred shares at $1,000 each for $2.5 million in gross proceeds to help fund the transaction and for general purposes. Each preferred share is immediately convertible, at the holder’s option and subject to stated limits, into common stock based on the formula: Original Share Price divided by 0.6249.
Biofrontera plans to file a resale registration statement for the common stock underlying the newly issued preferred shares within three days of closing and to seek effectiveness within stated SEC review timelines. The company believes its stockholders’ equity now exceeds $5 million, aligning with Nasdaq Listing Rule 5550(b)(1), with Nasdaq continuing to monitor compliance.
Biofrontera Inc. announced the closing of its restructuring and asset purchase agreement with Biofrontera AG, supported by an investment of $11 million led by existing investors. The company disclosed this update under Regulation FD, indicating it is being furnished rather than filed.
The closing marks completion of the transaction described, with the new capital noted alongside the deal. The press release providing details was issued on October 23, 2025 and is included as Exhibit 99.1.
Biofrontera Inc. (BFRI) received an initial Form 3 reporting by Christian Alexander Ansgar Link relating to a 09/16/2025 event. The filing states the reporting person is a member and chairman of the supervisory board of Biofrontera AG, which holds a 10% ownership interest in the Issuer. The filer is also a member of the management board of Deutsche Balaton Aktiengesellschaft, whose affiliates collectively hold approximately 62.2% of the voting stock of Biofrontera AG. The reporting person expressly disclaims any pecuniary interest in the shares held by Deutsche Balaton Aktiengesellschaft and Biofrontera AG. The Form 3 indicates no securities are beneficially owned directly or indirectly by the reporting person.
VV Beteiligungen Aktiengesellschaft filed an Initial Statement of Beneficial Ownership (Form 3) reporting indirect holdings in Biofrontera Inc. (BFRI) arising through affiliates. The filing notes an event date of 09/16/2025 and identifies the reporting person as a Director. VV Beteiligungen reports 400,000 shares of common stock held indirectly by Biofrontera AG and 58,884 shares held indirectly by Deutsche Balaton Aktiengesellschaft. In addition, the filer reports Series D convertible preferred stock convertible into 4,831,172 shares of common stock at a conversion price of $0.6249 per share; the preferred has no expiration and conversion is limited so the holder and affiliates cannot exceed 19.99% ownership on conversion. The filing states the reporting person and its affiliates collectively hold approximately 62.2% of the outstanding voting stock of Biofrontera AG and disclaim direct beneficial ownership except to the extent of indirect pecuniary interest.
Delphi Unternehmensberatung AG reported an initial beneficial ownership statement for Biofrontera Inc. (BFRI). The filing discloses 400,000 common shares held indirectly by Biofrontera AG and 58,884 common shares held indirectly by Deutsche Balaton Aktiengesellschaft. It also reports convertible preferred stock representing 4,831,172 underlying common shares held indirectly by Biofrontera AG, convertible at $0.6249 with a 19.99% ownership cap on conversion.
Hansjoerg Plaggemars filed an Initial Form 3 reporting his relationship to Biofrontera Inc. (BFRI). He is a director and explains he serves on the supervisory board of Biofrontera AG, which holds a 10% stake in the issuer. He also holds management roles in entities that together control ~62.2% of Biofrontera AG. The filing states no securities are beneficially owned by the reporting person.
Wilhelm Konrad Thomas Zours filed an initial Section 16 Form 3 reporting indirect beneficial ownership in Biofrontera Inc. (BFRI). He reports 400,000 common shares held by Biofrontera AG and 58,884 common shares held by Deutsche Balaton Aktiengesellschaft, both held indirectly. He also reports convertible preferred stock exercisable into 4,831,172 common shares at $0.6249 per share; the preferred has no expiration but conversion is capped to avoid >19.99% ownership on conversion. The filing includes managerial roles and ownership chains explaining indirect holdings.
Deutsche Balaton Aktiengesellschaft filed an Initial Statement of Beneficial Ownership reporting direct ownership of 58,884 shares of Biofrontera Inc. (BFRI) and indirect ownership of 400,000 common shares
The filer also reports indirect beneficial ownership of 4,831,172 common shares underlying Series D Convertible Preferred Stock convertible at $0.6249 per share, held by Biofrontera AG. The filer states it and affiliates control ~62.2% of Biofrontera AG voting stock and disclaims direct beneficial ownership except for indirect pecuniary interest. The preferred has no expiration and conversion is limited to prevent over 19.99% ownership on conversion.
Maria del Pilar de la Huerta Martinez filed an Initial Statement of Beneficial Ownership on Form 3 reporting indirect holdings in Biofrontera Inc. (BFRI). The filing states 400,000 shares of common stock are held indirectly by Biofrontera AG and the reporting person may be deemed to beneficially own those shares because she is the sole member of the management board of Biofrontera AG. The filing also reports ownership of Series D convertible preferred stock convertible into 4,831,172 shares of common stock at a conversion price of $0.0006 per share; the preferred is convertible at any time and has no expiration date. The reporting person is identified as a director and a 10% owner for the issuer, and disclaims direct beneficial ownership except for any indirect pecuniary interest. The filing notes that Biofrontera AG has the right to appoint a board representative and that Dr. Heikki Lanckriet has been deputized and filed a separate Section 16 report.
Biofrontera, Inc. reported results from a special shareholder meeting where shareholders holding 8,403,861 votes were present for proposals one, three, and four, and shareholders holding 6,820,211 votes were present for proposal two, constituting a quorum for all proposals. The filing states that the meeting was solicited under Regulation 14A and that there was no solicitation in opposition. The proxy statement filed on August 5, 2025 is cited as the source for the detailed descriptions of the proposals. The document indicates that the meeting "summarizes all matters voted on," but it does not include the vote tallies or explicit outcomes for each proposal within the provided text.